HiPP Biologique Risk Report

⚖️ Legal & Regulatory

Hipp Biologique faces regulatory challenges as some of its infant formula products have not met U.S. FDA standards. This issue primarily revolves around insufficient iron levels, which could potentially result in iron deficiency for infants consuming these products. As a result, several warnings and recalls have been issued, impacting the company's compliance reputation and possibly its market position in regulated markets.

• An August 8, 2021, announcement indicated that Able Groupe was recalling certain infant formula products due to insufficient iron levels, failing to meet U.S. FDA requirements.
• On August 10, 2021, it was reported that several baby formulas, including those by this company, were recalled for not having enough iron to meet FDA standards.
• By August 9, 2021, the Miami Herald reported that 19 baby formulas, some from this company, were recalled; eight of these could cause iron deficiency in infants.
• On October 11, 2021, Nigeria's NAFDAC warned against purchasing the company's infant formulas from U.S. sources, indicating regulatory concerns.